Enveric Biosciences initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Enveric Biosciences with a Buy rating and $10 price target. The company’s pipeline assets represent an early opportunity to invest in next-generation neuroplastogens, the analyst tells investors in a research note. The firm says Enveric is developing novel, small-molecule therapeutics as treatments for anxiety, depression, and other mental health disorders.